Evotec (NASDAQ:EVO) Upgraded to Buy by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Evotec (NASDAQ:EVO) from a hold rating to a buy rating in a research note issued to investors on Friday, MarketBeat.com reports.

Separately, Royal Bank of Canada raised Evotec from a sector perform rating to an outperform rating in a research note on Thursday, January 18th.

Evotec Price Performance

EVO opened at $7.25 on Friday. The stock’s 50-day moving average price is $7.42 and its 200 day moving average price is $8.79. Evotec has a 12-month low of $6.83 and a 12-month high of $13.49.

Institutional Investors Weigh In On Evotec

A number of hedge funds have recently bought and sold shares of the stock. Mubadala Investment Co PJSC acquired a new stake in Evotec in the 4th quarter valued at about $53,931,000. Optiver Holding B.V. raised its position in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. OLD Mission Capital LLC acquired a new stake in Evotec in the 4th quarter valued at about $141,000. Finally, Quadrant Capital Group LLC acquired a new stake in Evotec in the 4th quarter valued at about $25,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.